Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
3 June 2013 |
Main ID: |
EUCTR2009-015987-32-PL |
Date of registration:
|
06/01/2010 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
An Extension Treatment Protocol for Subjects who have Participated in a Phase 3 Study of Tivozanib Hydrochloride vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)
|
Scientific title:
|
An Extension Treatment Protocol for Subjects who have Participated in a Phase 3 Study of Tivozanib Hydrochloride vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301) - NA |
Date of first enrolment:
|
17/02/2010 |
Target sample size:
|
350 |
Recruitment status: |
Authorised-recruitment may be ongoing or finished |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-015987-32 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: yes
Other trial design description: Subjects who demonstrate DP on sorafenib may start tivozanib hydrochloride treatment
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 2
|
Phase:
|
|
|
Countries of recruitment
|
Bulgaria
|
Canada
|
Chile
|
Czech Republic
|
France
|
Hungary
|
India
|
Italy
|
Poland
|
Romania
|
Russian Federation
|
Serbia
|
Ukraine
|
United Kingdom
|
United States
| |
Contacts
|
Name:
|
Margaret M. Taleff/ Vice President
|
Address:
|
75 Sydney Street
MA 02139
Cambridge
United States |
Telephone:
|
617 299-5856 |
Email:
|
mtaleff@aveopharma.com |
Affiliation:
|
AVEO Pharmaceuticals, Inc. |
|
Name:
|
Margaret M. Taleff/ Vice President
|
Address:
|
75 Sydney Street
MA 02139
Cambridge
United States |
Telephone:
|
617 299-5856 |
Email:
|
mtaleff@aveopharma.com |
Affiliation:
|
AVEO Pharmaceuticals, Inc. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Subjects who have discontinued treatment in the AV-951-09-301 protocol and have been undergoing tumor assessment and/or survival follow-up will not need to meet the eligibility criteria (defined below) for their long term follow-up in the current study
1. The subject must have participated on Protocol AV-951-09-301, and must meet either of the following bulleted criteria:
- Demonstrated disease progression per RECIST during treatment with sorafenib, OR
- Demonstrated clinical benefit [complete response (CR), partial response (PR), or stable disease (SD) per RECIST] and acceptable tolerability after treatment with tivozanib hydrochloride or sorafenib on protocol AV-951-09-301
2. ECOG performance status = 2 (see Appendix C) and life expectancy = 3 months.
3. If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.
4. Ability to give written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 167 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 79
Exclusion criteria: 1. Newly identified CNS malignancies or documented progression of CNS metastases; subjects will be allowed only if the CNS metastases have been adequately treated with radiotherapy or surgery. For subjects receiving steroid therapy please refer to Section 6.3 for allowed steroid maintenance therapy
2. Duration since last dose on Protocol AV-951-09-301:
For subjects continuing tivozanib hydrochloride or sorafenib (subjects who demonstrated clinical benefit and acceptable tolerability during treatment with tivozanib hydrochloride or sorafenib on protocol AV-951-09-301): more than 2 weeks since last dose of tivozanib hydrochloride or sorafenib
For subjects initiating tivozanib hydrochloride (ie demonstrated disease progression during treatment with sorafenib): more than 4 weeks since last dose of sorafenib. Subjects demonstrating disease progression due to CNS metastasis will be allowed up to 8 weeks since last dose of sorafenib in order to complete treatment for CNS metastasis
3. Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug
4. Any of the following hematologic abnormalities:
· Hemoglobin < 9.0 g/dL
· ANC < 1500 per mm
· Platelet count < 75,000 per mm3
· PT or PTT >1.5 × ULN
3. Any of the following serum chemistry abnormalities:
· Total bilirubin > 1.5 × ULN (or > 2.5 × ULN for subjects with Gilbert’s syndrome)
· AST or ALT > 2.5 × ULN (or > 5 × ULN for subjects with liver metastasis)
· Alkaline phosphatase > 2.5 × ULN (or > 5 × ULN for subjects with liver or bone metastasis)
· Creatinine > 2.0 × ULN
· Proteinuria > 3+ by urinalysis or urine dipstick
6. If female, pregnant or lactating
7. Sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures, while on study and for at least 50 days after the last dose of study drug. Sexually active male subjects must use adequate contraceptive measures, while on study and for at least 90 days after the last dose of study drug. All fertile male and female subjects,and their partners,must agree to use a highly effective method of contraception. Effective birth control includes (a) IUD plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides
(creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.)
8. Uncontrolled hypertension: systolic blood pressure > 150 mmHg or diastolic blood pressure >100 mmHg on 2 or more antihypertensive medications, documented on 2 consecutive measurements taken at least 24 hours apart.
9. Unhealed wounds (including active peptic ulcers)
10. Serious/active infection or infection requiring parenteral antibiotics
11. Life-threatening illness or organ system dysfunction compromising safety evaluation
12. Psychiatric disorder, altered mental status precluding informed consent or necessary testing
13. Inability to comply with protocol requirements
14. Treatment with another anti-cancer therapy or participation in another interventional protocol (excluding AV-951-09-301)
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Renal Cell Carcinoma MedDRA version: 14.1
Level: PT
Classification code 10067946
Term: Renal cell carcinoma
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
Therapeutic area: Diseases [C] - Cancer [C04]
|
Intervention(s)
|
Product Name: Tivozanib Hydrochloride Product Code: AV-951 Pharmaceutical Form: Capsule CAS Number: 682745-41-1 Current Sponsor code: AV-951 Other descriptive name: KRN951; Ki19294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5-
Product Name: Tivozanib Hydrochloride Product Code: AV-951 Pharmaceutical Form: Capsule CAS Number: 682745-41-1 Current Sponsor code: AV-951 Other descriptive name: KRN951; Ki19294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0-
Trade Name: Nexavar Pharmaceutical Form: Film-coated tablet INN or Proposed INN: SORAFENIB TOSILATE CAS Number: 475207-59-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-
|
Primary Outcome(s)
|
Primary end point(s): •provide access to tivozanib hydrochloride for subjects who participated in AV-951-09-301 and AV-951-09-902 and failed sorafenib treatment on either protocol •provide access to tivozanib hydrochloride for subjects who participated in AV-951-09-301 and demonstrated clinical benefit and acceptable tolerability to tivozanib hydrochloride •provide access to sorafenib subjects who participated in AV-951-09-301 and demonstrated clinical benefit and acceptable tolerability to sorafenib •to assess long term safety in subjects who continue treatment with tivozanib hydrochloride
|
Main Objective: · To allow access to tivozanib hydrochloride for subjects who participated in Protocol AV-951-09-301 and AV-951-09-902 and failed sorafenib treatment on either protocol. · To allow long-term access to tivozanib hydrochloride for subjects who participated in Protocol AV-951-09-301 and demonstrated clinical benefit and acceptable tolerability to tivozanib hydrochloride · To allow long-term access to sorafenib for subjects who participated in Protocol AV-951-09-301 and demonstrated clinical benefit and acceptable tolerability to sorafenib ·To assess long-term safety in subjects who continue treatment with tivozanib hydrochloride
|
Timepoint(s) of evaluation of this end point: As per study protocol
|
Secondary Objective: · To determine the objective response rate (ORR), duration of response (DR), and progression-free survival (PFS) of subjects who continue treatment with tivozanib hydrochloride or sorafenib · To determine the ORR, DR, and PFS of subjects who receive tivozanib hydrochloride after failure of sorafenib · To determine overall survival (OS) of subjects who continue treatment with tivozanib hydrochloride or sorafenib
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: ORR and DR as well as PFS are measured every two cycles (2 months) by CT scans. OS is assesed every 2 months following treatment discontinuation.
|
Secondary end point(s): - to determine the ORR, DR and PFS on patients who continue treatment with Tivozanib Hydrochloride or Sorafenib, or who initiate treatment with Tivozanib Hydrochloride after failure on Sorafenib
- and to determine OS of subjects who continue treatment with Tivozanib Hydrochloride or Sorafenib
|
Secondary ID(s)
|
2009-015987-32-FR
|
NCT01076010
|
AV-951-09-902
|
Source(s) of Monetary Support
|
AVEO Pharma Limited
|
AVEO Pharmaceuticals, Inc.
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|